Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week

January 10, 2025 8:30 AM

LAS VEGAS, NV / ACCESSWIRE / January 10, 2025 / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025, in San Francisco, California. Alyea is developing innovative, actionable solutions intended to help end the opioid crisis with its lead...

Read more

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

January 10, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and...

Read more

Lumira Ventures Announces Promotion of Suman Rao to Principal

January 10, 2025 7:00 AM

TORONTO, ON / ACCESSWIRE / January 10, 2025 / Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare...

Read more

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

January 10, 2025 6:30 AM

LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV)BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has achieved ISO 26000 verification, an internationally recognized standard. This achievement highlights BioInvent's dedication to...

Read more

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

January 9, 2025 3:00 PM

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body...

Read more

The FDA Continues to Intimidate Doctors and Defraud the American Public

January 9, 2025 10:00 AM

The Golden Gift announced today that affordable plasma interventions can have significant health and economic benefits to prevent or manage age-related conditions that account for a majority of our nation's $4.5 trillion in annual health care expenditures: https://www.youngplasmastudy.com.Plasma was approved for medical use by the Federal Food, Drug, and Cosmetic Act of 1938 (FDCA) and since the formation of the Junior Red Cross on November 1,...

Read more

Genvara Biopharma to Present at Biotech Showcase 2025 and Lytham Partners 2025 Investor Healthcare Summit

January 8, 2025 12:40 PM

Genvara Biopharma, Inc., a biopharmaceutical company developing pharmacogenetically-targeted therapies for cardiovascular diseases acting through novel mechanisms of action, today announced that Thomas Keuer, Chief Executive Officer, will present at the Biotech Showcase 2025, taking place January 13-15, 2025 in San Francisco, California and Genvara will also participate in a webcasted company presentation at the Lytham Partners 2025 Investor...

Read more

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

January 8, 2025 8:30 AM

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the...

Read more

Bionoid Pharma, Inc. Reports Over $100,000 in Revenue Following Binding LOI With Your Supplement Supply Store Ltd.

January 8, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the generation of over $100,000 in revenue following the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd. This significant milestone underscores the strategic value of the agreement and demonstrates the potential of Bionoid's growth strategy.The LOI with Your Supplement Supply Store Ltd. represents a pivotal step in Bionoid's expansion into...

Read more

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

January 8, 2025 2:20 AM

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatmentOne complete response (CR) and one partial response (PR)The treatment has been well-tolerated with no safety or tolerability concernsStudy now expanding to additional clinical investigational sites and patient enrollment on track...

Read more

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

January 8, 2025 2:20 AM

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events even at the highest doses tested.Phase 1 part B evaluating BI-1910 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) initiatedBioInvent is developing...

Read more

Lifeloc Technologies Secures $750,000 Financing to Support Growth and Innovation

January 7, 2025 4:38 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a leading provider of portable breath alcohol testing devices and related solutions, today announced the successful closing of a $750,000 financing transaction through a subordinated debenture agreement with Diamond Bridge Capital, LP. The financing also includes a warrant granting Diamond Bridge Capital the right to purchase up to 62,500 shares of Lifeloc's common stock at a strike price of $4.50 per...

Read more

Next Gen Diagnostics and Sheba Medical Center Announce Agreement for NGD to Sequence and Analyze Unique Collection of Highly Resistant Bacterial Infections

January 7, 2025 11:00 AM

CAMBRIDGE, MA and RAMAT GAN, ISRAEL / ACCESSWIRE / January 7, 2025 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based detection of transmission and for the determination of bacterial susceptibility to antibiotics, and Sheba Medical Center, the largest medical complex in Israel and the Middle East, announce an agreement providing for the sequencing and...

Read more

ProteinQure Strengthens Leadership Team with Key Appointments to Accelerate Translational and Clinical Development Programs

January 7, 2025 10:45 AM

ProteinQure, a leader in computational peptide design, is proud to announce the addition of two distinguished leaders to its team. Dr. Dave Garman has been appointed as Vice President of Translation and Development, and Dr. Edward Garmey has joined as consulting Chief Medical Officer. These strategic hires strengthen ProteinQure's ability to advance its clinical asset PQ203 and additional programs in their pipeline. PQ203 is a first-in-class...

Read more

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

January 7, 2025 9:15 AM

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces its conducive position in connection with the recently...

Read more

Adnexus Biotechnologies Inc. Unveils AI-Driven Malaria Cure with Trapicolast

January 7, 2025 7:00 AM

Adnexus Biotechnologies Inc. proudly announces the launch of Trapicolast, a pioneering antimalarial drug developed through its innovative AI-powered Sutra™ platform. Integrating AI Platform discovered ADX1 and ADX2, this breakthrough medication targets dual mechanisms within the Plasmodium parasite, attacking both the apicoplast and vesicular trafficking pathways.A New Era in Malaria TreatmentTraditional antimalarial treatments have primarily...

Read more

GlyTherix and 3D Imaging Establish Strategic Alliance for Radiopharmaceutical Development and Manufacturing in the U.S.

January 3, 2025 7:45 AM

SYDNEY, AUSTRALIA and LITTLE ROCK, AR / ACCESSWIRE / January 3, 2025 / GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, are pleased to announce the execution of a Master Service Agreement. This collaboration combines 3DI's cutting-edge radiopharmaceutical manufacturing expertise with GlyTherix's...

Read more

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

December 19, 2024 7:00 PM

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings.Details of the events are as follows:Event: BIO Partnering @ JPMDate: January 13 - 16, 2025Registration:...

Read more

PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025

December 19, 2024 1:45 PM

MINNEAPOLIS, MN / ACCESSWIRE / December 19, 2024 / PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.John Lai,...

Read more

IPA to Present at The Microcap Conference 2025

December 19, 2024 10:15 AM

VICTORIA, BC / ACCESSWIRE / December 19, 2024 / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ.IPA's management team will deliver a...

Read more